Skip to main content

Table 3 Summary of data obtained from different studies on kidney dosimetry for 177 Lu octreotate

From: Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy

  The present study, Gothenburg Valkema et al., Rotterdam [ [18]] Garkavij, et al., Lund [ [20]] Sandström et al., Uppsala [ [19]] Wehrmann et al., Bad Berka [ [17]] Cremonesi et al., Milan [ [15]]
Kidney protection Lysine, arginine Lysine, arginine Vamin Vamin Lysine, arginine ND
Number of patients 33 37 16 24 61 10
A administered/treatment cycle (GBq) mean (range) (3.4 to 8.2) (1.8 to 7.4) 7.4 7.4 5.4 (2.5 to 7.4) (3.7 to 7.4)
Treatment cycles per patient 1 to 5 3 to 7 2 to 4 Only first treatment cycle 1 to 4 ND
D/A administered (Gy/GBq) mean (SD) 0.80 (0.30), 0.60 (0.17)*   0.97 (0.24), 1.15 (0.29)*, 0.81 (0.21)**, 0.90 (0.21)*** 0.98 (0.73), 0.71 (0.25)*, 0.65 (0.25)** 0.9 (0.3) 0.62 (median)
D/A administered (Gy/GBq) range 0.33 to 2.4 Gy/GBq, 0.29 to 1.2 Gy/GBq* 7.3 to 27 Gy   2.4 to 13 Gy (right)** 0.5 to 1.7 Gy/GBq 0.45 to 18 Gy/GBq (median range)
D/A administered for treatment cycle 1 (Gy/GBq) mean (range) (SD) 0.84 (0.38 to 1.7) (0.29)    0.98 (0.73), 0.71 (0.25)*, 0.65 (0.25)**   
Imaging time points 1 h, days 1, 2, and 7 ND, but several days 0.5 h, days 1, 4, and 7 (treatment cycle 1 to 2) days 1,and 4 (treatment cycle 3 to 4) SPECT at day1 and/or day 4 1 h, days 1, 4, and 7 (treatment cycle 1) SPECT at all time points 0, 3, 20, 44, and 68 h up to 48 h
Scintigraphic method Planar imaging Planar imaging Planar imaging, SPECT Planar imaging, SPECT Planar imaging Planar imaging
Quantification method CV, *PA, CT for kidney mass CV CV attenuation map CT for kidney mass, *different background, **SPECT to scale the time-activity curve, ***SPECT for voxel dosimetry *SPECT organ VOI, **SPECT small VOI (4 cm3) CV CV
Dosimetry MIRD MIRDOSE3 MIRD OLINDA MIRD 16, MEDISO, OLINDA with S values for absorbed dose calculation OLINDA/EXM
  1. CV, conjugate-view method; PA, posterior-anterior view method; A administered, administered activity; D, mean absorbed dose; ND, not defined. Note that some studies give data in Gy and other in Gy/GBq, and some use mean values while other use median values. The asterisk (*) is for guiding the reader, which quantification method was used in providing the mean absorbed doses in each study compared.